Outlook Therapeutics Inc has experienced a rollercoaster ride in the biotech sector, with its stock price fluctuating from a high of $9.25 to a low of $0.87, raising questions about its long-term viability and strategic direction.

Outlook Therapeutics, a clinical-stage biopharmaceutical company, focuses on developing biosimilar therapeutics for immunology and oncology, with a market presence on the Nasdaq stock exchange.